Basit öğe kaydını göster

dc.contributor.authorErdal, E.
dc.contributor.authorSayman, Haluk
dc.contributor.authorTürkmen, Cüneyt
dc.contributor.authorAral, Ferihan
dc.contributor.authorYıldız, Özcan
dc.contributor.authorOkutur, Kerm
dc.contributor.authorParalı, E.
dc.contributor.authorDeğer, C.
dc.contributor.authorTunalıoğlu, A.
dc.contributor.authorSar, Christina
dc.contributor.authorAsan, Simona
dc.contributor.authorSümer, Fulya Erendağ
dc.contributor.authorÖzel, Özgür
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T20:04:31Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T20:04:31Z
dc.date.issued2015
dc.identifier.citationErdal, E., Sayman, H., Türkmen, C., Aral, F., Yıldız, Ö., Okutur, K. ... Özel, Ö. (2015). Cost-effectiveness of sorafenib for treatment of radioactive iodine (rai)-refractory locally advanced/metastatic differentiated thyroid cancer (dtc) in Turkey. Value in Health içinde ( A203-A204. ss.). https://dx.doi.org/10.1016/j.jval.2015.03.1178en_US
dc.identifier.issn1098-3015
dc.identifier.issn1524-4733
dc.identifier.urihttps://dx.doi.org/10.1016/j.jval.2015.03.1178
dc.identifier.urihttps://hdl.handle.net/20.500.12511/4064
dc.descriptionWOS: 000354498503198en_US
dc.description.abstractOBJECTIVES: Sorafenib is the first product approved for treatment of RAI refractory locally advanced/metastatic DTC patients. This study was conducted in order to analyze cost-effectiveness of sorafenib for treatment of patients with RAI refractory locally advanced/metastatic DTC in Turkey. METHODS: A cohort partition model assigning patients to one of three health states according to the proportion of patients who are progression-free, progressed, or dead in each 28-days cycle was adapted to Turkish setting. The incremental cost-effectiveness ratios (ICER) were calculated per quality-adjusted life years (QALYs) and life-years (LYs) gained. Turkish payer’s perspective was taken and time-horizon was set as patient’s lifetime (maximum 30 years). Sorafenib was compared to the best supportive care (BSC) within the model since there are no agents for treatment of patients on this stage of the disease. Essential clinical inputs were derived from DECISION trial and local resource-utilization data were based on expert opinions through an expert panel. Sensitivity of the results was evaluated in terms of key inputs by deterministic oneway and probabilistic sensitivity analyses. All costs were calculated in Turkish Liras (TL) and converted to USD using TL/USD currency rate as 2.2 (mid-2014). RESULTS: Total cost of sorafenib-treated patients is 24,384 USD higher compared to BSC. Besides, sorafenib is associated with increments of 1.29 LYs and 0.80 QALYs compared to BSC. The ICER of sorafenib per LYs and QALYs gained compared to BSC were determined as 18,851 USD and 30,485 USD respectively. One-way sensitivity analysis demonstrated that results are not sensitive to the changes in model inputs and pharmacoeconomic analysis results were validated by probabilistic sensitivity analysis. CONCLUSIONS: Sorafenib is cost-effective for treatment of patients with RAI refractory locally advanced/metastatic DTC compared to BSC with an ICER value below the willingness-to-pay threshold (3-times GDP per capita ─ 32,346 USD) for Turkey.en_US
dc.language.isoengen_US
dc.publisherElsevier Scienceen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSorafeniben_US
dc.subjectRefractoryen_US
dc.titleCost-effectiveness of sorafenib for treatment of radioactive iodine (rai)-refractory locally advanced/metastatic differentiated thyroid cancer (dtc) in Turkeyen_US
dc.typeconferenceObjecten_US
dc.relation.ispartofValue in Healthen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.identifier.volume18en_US
dc.identifier.issue3en_US
dc.identifier.startpageA203en_US
dc.identifier.endpageA204en_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1016/j.jval.2015.03.1178en_US
dc.identifier.wosqualityQ1en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster